

Juan-Ramón Larrubia, PhD, Series Editor

## Pathogenesis of occult chronic hepatitis B virus infection

Rocio Aller de la Fuente, María L Gutiérrez, Javier Garcia-Samaniego, Conrado Fernández-Rodríguez,  
Jose Luis Lledó, Gregorio Castellano

Rocio Aller de la Fuente, Gastroenterology, Hospital Clinico Universitario Valladolid, Institute of endocrinology and Nutrition, Medical School, University of Valladolid, 47003 Valladolid, Spain  
María L Gutiérrez, Service of Gastroenterology, Hospital Universitario Fundación Alcorcón, Av Budapest-1, 28922 Alcorcón, Madrid, Spain

Javier Garcia-Samaniego, Gastroenterology Department, Hospital Carlos III, c/ Sinesio Delgado, 28029 Madrid, Spain

Conrado Fernández-Rodríguez, Service of Gastroenterology, Hospital Universitario Fundación Alcorcón, Av Budapest-1, 28922 Alcorcón, Madrid, Spain

Jose Luis Lledó, Service of Gastroenterology, Hospital Universitario Fundación Alcorcón, Av Budapest-1, 28922 Alcorcón, Madrid, Spain

Gregorio Castellano, Hospital Universitario 12 de Octubre, Av de Andalucía 28041, 28039 Madrid, Spain

Author contributions: Aller de la Fuente R and Gutiérrez ML contributed towards the conception and design of the review; Garcia-Samniego J, Fernández-Rodríguez C, Lledó JL and Castellano G contributed equally to the supportive work and supervision.

Correspondence to: Dr. Rocio Aller de la Fuente, Gastroenterology Department, Hospital Clinico Universitario Valladolid, Institute of Endocrinology and Nutrition, Medical School, University of Valladolid, Avenida Ramón y Cajal s/n., 47003 Valladolid, Spain. [roaller@yahoo.es](mailto:roaller@yahoo.es)

Telephone: +34-983-420000 Fax: +34-983-420000

Received: August 6, 2010 Revised: January 22, 2011

Accepted: January 29, 2011

Published online: March 28, 2011

the viral DNA, is due in most cases to the strong suppression of viral replication and gene expression that characterizes this "occult" HBV infection; although the mechanisms responsible for suppression of HBV are not well understood. The majority of OBI cases are secondary to overt HBV infection and represent a residual low viremia level suppressed by a strong immune response together with histological derangements which occurred during acute or chronic HBV infection. Much evidence suggests that it can favour the progression of liver fibrosis and the development of hepatocellular carcinoma.

© 2011 Baishideng. All rights reserved.

**Key words:** Occult hepatitis B virus infection; Hepatitis B virus-DNA; Anti-HBc alone; Hepatitis B virus; Hepadnaviral hepatitis; Occult viral persistence; Primary occult infection; Secondary occult infection; Virus reactivation

**Peer reviewer:** Tsianos Epameinondas, MD, PhD, Professor, 1st Division Of Internal Medicine and Hepato-Gastroenterology Unit, Medical school University of Ioannina, PO Box 1186 Ioannina 45110, Greece

Aller de la Fuente R, Gutiérrez ML, Garcia-Samaniego J, Fernández-Rodríguez C, Lledó JL, Castellano G. Pathogenesis of occult chronic hepatitis B virus infection. *World J Gastroenterol* 2011; 17(12): 1543-1548 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v17/i12/1543.htm> DOI: <http://dx.doi.org/10.3748/wjg.v17.i12.1543>

### Abstract

Occult hepatitis B infection (OBI) is characterized by hepatitis B virus (HBV) DNA in serum in the absence of hepatitis B surface antigen (HBsAg) presenting HBsAg-negative and anti-HBc positive serological patterns. Occult HBV status is associated in some cases with mutant viruses undetectable by HBsAg assays; but more frequently it is due to a strong suppression of viral replication and gene expression. OBI is an entity with world-wide diffusion. The failure to detect HBsAg, despite the persistence of

### INTRODUCTION

Hepatitis B virus (HBV) infection is a major global health problem. It is estimated that about 350 000 000 individuals are infected by HBV; infection can induce a wide spectrum of clinical forms, ranging from a healthy carrier state to cirrhosis and hepatocellular carcinoma<sup>[1]</sup>. HBV infection is usually diagnosed when circulating hepatitis B sur-

face antigen (HBsAg) is detected. However, the availability of highly sensitive molecular biology techniques has also allowed the identification of HBV infection in HBsAg-negative individuals, with or without circulating antibodies to HBsAg (anti-HBs) and/or hepatitis B core antigen (anti-HBc)<sup>[2-5]</sup>. Furthermore, it is estimated that as much as one third of the world population have been exposed to HBV<sup>[6]</sup>. Many of these individuals may unknowingly carry the virus. The natural history of chronic HBV infection is highly heterogeneous as many host, virus and environmental factors play an integrated role in affecting rates of disease progression and long term clinical outcomes.

## CHRONIC HBV INFECTION AND ITS VIROLOGICAL PHASES

The natural course of chronic infection includes four phases based on the virus-host interaction: immune tolerance, immune clearance, low or non-replication, reactivation and HBsAg negative (occult) HBV<sup>[6-8]</sup>.

### **Immune tolerance phase**

This phase is characterized by presence of hepatitis B e antigen (HBeAg), high serum levels of HBV DNA, normal or minimally elevated serum alanine aminotransferase (ALT) and normal liver or only minimal histological activity. The immunotolerant phase may persist for 10-30 years in perinatally infected subjects, whereas it is generally short-lived or absent in childhood or adult-acquired HBV infection.

### **Immune clearance phase**

This initiates when immune tolerance to the virus is lost and the immune response starts to kill infected hepatocytes. This phase is characterized by fluctuating, but progressively decreasing, HBV DNA levels, high levels of ALT and hepatic necroinflammation. Serum HBV DNA levels are > 20000 IU/mL ( $10^5$  copies/mL) in the phase of HBeAg positive chronic hepatitis and may remain elevated or drop rapidly at the time of anti-HBe seroconversion.

### **Inactive carrier state**

An important outcome of the active immune response is seroconversion from HBeAg to anti-HBe, with transition to the third phase of inactive HBsAg carrier state, characterized by HBeAg negativity and anti-HBe positivity, low levels of HBV DNA < 2000 IU/mL ( $10^4$  copies/mL), normal ALT and inactive liver histology.

### **Reactivation phase**

Some inactive HBsAg carriers may develop HBV reactivation while remaining anti-HBe positive. This phase is characterized by HBeAg negativity with anti-HBe positivity, HBV DNA levels > 2000-20000 IU/mL ( $10^4$ - $10^5$  copies/mL), high ALT and moderate or severe necroinflammation with variable amounts of fibrosis on liver biopsy (HBeAg negative chronic hepatitis).

### **HBs negative (occult) HBV**

A final phase of chronic HBV infection may eventually follow in some long term carriers, with loss of HBsAg but persistence of HBV DNA in liver. These cases usually do not have active liver disease but show the histological consequences of previous damage with variable amounts of residual fibrosis. Immunosuppression, however, may cause HBV reactivation and sometime severe exacerbation of liver disease with HBsAg, HBV DNA, and even HBeAg rebound.

## DEFINITION OF HBsAg LOSS

In "inactive carriers" the HBsAg may become undetectable which is defined as HBsAg loss. A loss of HBsAg is a sign for deep and usually durable suppression of HBV DNA replication and usually announces a stable status of recovery, even though other complications caused by pre-existing liver cirrhosis or fibrosis or an elevated risk for development of hepatocellular carcinoma can still lead to severe complications<sup>[9,10]</sup>. However, HBsAg may reappear and replication may reincrease, especially if the HBsAg loss was observed during a period of antiviral therapy. The spontaneous HBsAg loss in anti-HBe-positive asymptomatic HBsAg carriers has long been recognized as a very rare event with increasing probability during long term follow up. Accordingly, a cumulative rate of HBsAg seroclearance of 8.1% was described after the first 10 years of infection. Chu *et al*<sup>[11]</sup> observed that the cumulative probability of HBsAg seroclearance increased to 24.9% after 20 years and to 44.7% after 25 years of HBV infection. The authors also pointed out that age at infection, sustained remission of liver disease and male sex were factors independently associated with HBsAg seroclearance.

## ETIOPATHOGENESIS OF OCCULT HEPATITIS B INFECTION

Occult HBV is found more frequently in patients with serologic evidence of HBV infection (anti-hepatitis B core antibody positive) than in core antibody-negative individuals<sup>[12,13]</sup>. Occult HBV is found in a significant proportion of patients with chronic hepatitis due to hepatitis C virus, with HBV DNA detectable in up to 30% of serum samples and 50% of liver biopsies<sup>[12]</sup>. Occult HBV infection is defined as the existence of HBV DNA in the serum, cells of the lymphatic (immune) system, and/or hepatic tissue in the absence of serum HBsAg. Most frequently, occult HBV infection follows resolution of acute hepatitis and continues indefinitely after clearance of HBsAg and biochemical improvement in liver function<sup>[13-17]</sup>. Recent estimates suggest that up to 20% of individuals with occult HBV carriage evidenced by HBV DNA detection could be nonreactive for anti-HBc or any other serological indicator of exposure to HBV<sup>[15]</sup>. Although viruses with replication deficits could theoretically explain occult HBV, the finding of cccDNA, RNA transcripts, and pregenomic replicative RNA intermediates in a large proportion of pa-

tients suggests that most occult infections are due to low-level replication of wild-type virus<sup>[19,20]</sup>. In addition, the transmissibility of acute HBV *via* liver transplant or blood product transfusion from donors with occult infection<sup>[21-23]</sup> provides evidence against the presence of defective viruses. Occult HBV may also result from mutations in HBsAg coding or transcription control regions that alter antigenicity or expression levels<sup>[24-26]</sup>. Such mutant viruses have been reported as the sole circulating strain in up to 40% of patients with occult HBV<sup>[27-30]</sup>. Occult hepatitis B infection (OBI) has been detected in the following clinical situations: (1) chronic hepatitis unrelated to HVC, atypical alcoholic hepatitis and hepatocellular carcinoma (HCC); (2) viral reactivation following immunosuppression; and (3) transmission through transplantation, transfusion or experimental transmission to chimpanzees<sup>[31]</sup>. Low level HBV DNA has been detected in liver tissue of patients with HCC<sup>[32]</sup> and in serum of blood donors and their recipients. Occult silent or serologically negative HBV infection was reported for the first time more than 20 years ago in the context of blood transfusion *via* the transmission of HBV by a donor positive for anti-HBc as the only marker of HBV infection<sup>[33]</sup>. Schematically, the available data suggest that (a) the host's immune response; (b) coinfection with others infectious agents; and (c) epigenic factors may play important roles in inducing the occult status.

## VIROLOGICAL ASPECTS

The molecular basis of occult infection is strictly related to the peculiar life cycle of the HBV. A fundamental step is the conversion of the ~3 kb relaxed circular genome into a covalently closed-circular DNA (cccDNA), a long lived HBV replicative intermediate that persists in the cell nuclei as a stable chromatinized episome and that serves as a template for gene transcription<sup>[34,35]</sup>. The stability and long-term persistence of viral cccDNA molecules, together with the long half-life of hepatocytes, imply that HBV infection, once it has occurred, may possibly continue for life<sup>[36]</sup>. Reduced HBV viraemia may result from extrahepatic HBV replication, such as in peripheral blood mononuclear cells or from coinfection with others viruses, especially with VHC, which down regulate HBV replication<sup>[31]</sup>.

### **Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen**

Several recent reports have shown that HBV could be frequently transmitted to recipients from donors who have antibodies to hepatitis B core antigen (anti-HBc) through liver transplantation. Marusawa *et al*<sup>[19]</sup> provide the molecular evidence of latent HBV infection accompanied with ongoing viral replication in the liver tissue of anti-HBc-positive healthy individuals. They have demonstrated that HBV DNA was detectable in 13 of 14 healthy donors who were positive for both anti-HBc and antibodies to hepatitis B surface antigen (anti-

HBs), but in none of 3 who were positive for anti-HBs alone. The detected HBV genomes from these subjects included cccDNA and pregenomic RNA, the replication intermediate of HBV. Notably, 5 of 7 cases tested were predominantly infected with wild type HBV strains without any mutations in the precore and core promoter regions under the presence of circulating antibody to hepatitis B e antigen, but we can not draw conclusions because of the small number of patients.

Therefore the majority of healthy individuals positive for anti-HBc, which had been assumed to denote a past history of transient HBV infection, were latently infected with the episomal form of HBV accompanied by ongoing viral replication and few nucleotide mutations in the precore and core regions.

### **Why are the occult HBV carriers HBsAg negative despite the presence in their liver of episomal, free HBV genomes?**

This is an unresolved question. Some of these individuals are infected by viral variants either producing an antigenically modified HBV S protein undetectable by the available HBsAg assays<sup>[37]</sup>, or carrying mutations capable of inhibiting S gene expression and/or viral replication<sup>[38,39]</sup>. The occult infection appears to be mostly due to a strong suppression of viral replication and gene expression affecting viruses whose genetic variability is comparable to that of HBV strains from individuals with "overt" chronic HBV infection<sup>[40]</sup>.

## EXPERIMENTAL OCCULT HBV INFECTION

Recent studies<sup>[41]</sup> on this silent form of hepadnavirus carriage in an experimental woodchuck hepatitis virus (WHV) infection, which is considered to be the closest natural model of HBV disease, revealed that the life-long occult persistence of traces of pathogenic virus is an invariable consequence of recovery after hepadnaviral invasion and that this state always co-exists with a steady low-rate virus replication in both the liver and the lymphatic system. This experimental model has been validated during the last 2 decades as one of the most valuable tools in reach on hepatitis B<sup>[42,43]</sup>. Importantly, this serologically concealed infection can be accompanied by development of hepatocellular carcinoma in convalescent animals and is transmittable from mothers to offspring as an asymptomatic, indefinitely long infection which involves the lymphatic system but not always the liver<sup>[44]</sup>. Furthermore, it became apparent that the detection of anti-WHc in the absence of other serological indicators of infection is a reliable indicator of occult WHV persistence<sup>[45]</sup>. This state, which is similar in strength to HBV-specific cytotoxic T cell (CTL) and T helper lymphocyte responses detectable years after resolution of acute hepatitis B<sup>[46,47]</sup>, is likely a consequence of sustained stimulation of the immune system with a viral protein produced during low-level virion assembly<sup>[15]</sup>. The high degree of compatibility between WHV and HBV infections and the data from studies on otherwise healthy anti-HBc-positive individuals suggest



that the occurrence of isolated anti-HBc could also be of value in identifying occult HBV persistence. The virus recovered from woodchucks with OBI remains infectious. It was observed that WHV harvested from PBMC isolated during OBI and *ex vivo* stimulated with lipopolysaccharide (LPS) induced classical acute WHV hepatitis in virus-naïve animals<sup>[45]</sup>. In the case of hepadnaviruses, studies on occult WHV infection point to a direct link between virus persistence and its lymphotropism. They also reveal that infection of the lymphatic system could be a natural and unavoidable consequence of hepadnavirus invasion and that, under certain circumstances, such as a low virus dose, lymphoid cells can be the only temporary or permanent site of virus propagation. Another important fact established through analysis of the WHV model is that a state of occult virus persistence is a normal and ultimate aftermath of WHV infection, which is symptomatic, followed by recovery, or serologically silent from the start. A generalized concept is proposed for the possible progression pathways and outcomes of hepadnaviral infection in relation to variable virus and/or variation of virus in the host. Because of significant virological and pathobiological similarities between HBV and WHV, and close analogies in the patterns of progression and outcomes of the induced liver disease, this concept might also be applicable to human HBV infection<sup>[14]</sup>.

## RELATIONSHIP OF OCCULT HEPADNAVIRAL INFECTION AND THE HOST'S IMMUNE SYSTEM

The host's immune-surveillance probably has a critical role in the development of occult HBV infection, as suggested by at least two arguments: (1) there is evidence showing that a vigorous memory T-cell response against HBV antigens is still present many years after clinical recovery from acute B hepatitis, probably because the long-lasting persistence of the occult infection produces a minute amount of antigens able to maintain an efficient antiviral T-cell response<sup>[46,47]</sup>; and (2) all the conditions inducing immunosuppression may provoke the reactivation of the occult HBV infection with the reappearance of the typical serological profile of the productive infection<sup>[48,49]</sup>. During occult infection a balance between the virus and the host's immune system is established, and as well as the cytotoxic T lymphocytes, the cytokines synthesized in the liver might also exert a control on HBV replication<sup>[16]</sup>. On the other hand, it also is conceivable that this extrahepatic pattern of virus expression is a consequence of another property of the virus that, at low doses, displays its natural predisposition for invading lymphoid cells. In this regard, of note are our findings documenting the existence of the cell-binding site in the preS1 domain of the WHV envelope which mediates a strictly host and cell-type-specific recognition. Synthetic analogues of the site have considerably greater ability to interact with woodchuck lymphoid cells than with hepatocytes<sup>[50]</sup>. Different molecular forms of HBV

DNA, including replicative intermediates and cccDNA, and viral RNA have been detected in lymphoid cells of patients with clinically evident hepatitis B<sup>[51,52]</sup>, although discrimination between synthesized *de novo* viral nucleic acids and those potentially adhered to the cell surface has not always been made. Also, traces of HBV antigens have been found on peripheral blood mononuclear cells isolated from actively infected individuals<sup>[53]</sup>. The observation that cultured peripheral blood mononuclear cells from WHsAg-positive animals produced infectious virus strongly argued that lymphoid cells can support the complete replication cycle of WHV<sup>[54]</sup>.

## TRANSMISSIBILITY OF MATERNAL OCCULT HEPADNAVIRAL INFECTION TO NEWBORNS

Vertical transmission of viral hepatitis is considered to be a cause of many perinatal viral infections, and it is postulated that a specific variant can influence virus tropism and outcome of infection in the newborn.

Since mother-to-child transmission is one of the main routes for HBV dissemination, it was important to determine whether hepadnavirus persistently carried as an occult infection can be passed from mothers to their newborns. To investigate this possibility, Michalak *et al*<sup>[44]</sup> have examined woodchuck offspring born in captivity and they found not only that such mothers transmit WHV to newborns but also that the induced infection is asymptomatic and progresses for years after birth in the absence of serum WHsAg, anti-WHs and, in contrast to convalescent adults, anti-WHc-antibodies. Results of these experiments revealed that under certain natural conditions long-term persistence of hepadnavirus can be maintained exclusively at an extrahepatic location. Thus, there were newborns that did not have any detectable WHV DNA in sequential liver biopsies, yet the viral genomes were expressed in livers of other offspring from the same litter. There also were offspring that initially had lymphoid-restricted patterns of WHV infection, yet at 19 mo after birth became liver WHV DNA reactive<sup>[55]</sup>.

Albeit maternal transmission of hepadnavirus from mother to offspring might differ in some aspects in humans and woodchucks, the essential pathobiological similarity between HBV and WHV suggests that HBV could also be passed from apparently healthy mothers convalescent from hepatitis B to their babies. Children born to these mothers may persistently carry traces of infectious virus and, possibly, have an increased long-term risk for the development of disorders of the lymphatic system and, in some cases, the liver.

## CONCLUSION

Occult HBV infection is defined as HBV DNA detection in serum or in the liver of HBsAg-negative patients with or without serologic markers of previous viral

exposure. With the introduction of highly sensitive diagnostic tests for viral proteins the paradigms of HBV infection were challenged. Accumulated evidence indicates that occult HBV can be both a source of virus contamination in blood and organ donations, as well as the reservoir from which full blown hepatitis can arise. The oncogenic potency of occult HBV persistence becomes progressively evident. Certain co-morbidities support occult HBV infection as co-infection with hepatitis C virus or human immunodeficiency virus. Persistence of OBI could involve different mechanisms: mutation or integration of the viral sequence which may alter HBsAg expression, decrease of HBV replication, or hindrance of HBsAg through circulating immune complex. OBI has important clinical implications: any case reports indicate that immunosuppression caused by chemotherapy<sup>[56]</sup>, immunomodulatory agents<sup>[57]</sup>, or immune deficiencies, such as HIV infection<sup>[58]</sup> or hematological malignancies<sup>[59]</sup>, can reactivate occult infection. However most patients with hepatitis B who recover from the infection do not experience any problems during their lives.

In the case of hepadnavirus, studies on occult WHV infection point to a direct link between virus persistence and its lymphotropism. Infection of the lymphatic system could be a natural and unavoidable consequence of hepadnavirus invasion and that, under certain circumstances, such as low virus dose, lymphoid cells can be the only temporary or permanent site of virus propagation. Occult HBV may also result from mutations in HBsAg coding or transcription control regions that alter antigenicity or expression levels<sup>[19,25,26]</sup>. In addition, the transmissibility of acute HBV *via* liver transplant or blood product transfusion from donors with occult infection<sup>[5,22,23]</sup> provides evidence against the presence of defective viruses.

## REFERENCES

- 1 Lee WM. Hepatitis B virus infection. *N Engl J Med* 1997; **337**: 1733-1745
- 2 Bréchet C, Hadchouel M, Scotto J, Fonck M, Potet F, Vyas GN, Tiollais P. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. *Proc Natl Acad Sci USA* 1981; **78**: 3906-3910
- 3 Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, Wands J, Sninsky J, Tiollais P. Transmission of hepatitis B from hepatitis-B-seronegative subjects. *Lancet* 1988; **2**: 1273-1276
- 4 Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. *J Infect Dis* 1991; **163**: 397-399
- 5 Lioriot MA, Marcellin P, Bismuth E, Martinot-Peignoux M, Boyer N, Degott C, Erlinger S, Benhamou JP. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. *Hepatology* 1992; **15**: 32-36
- 6 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat* 2004; **11**: 97-107
- 7 de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J, Rosenberg W, Valla D. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). *J Hepatol* 2003; **39** Suppl 1: S3-S25
- 8 Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; **45**: 529-538
- 9 Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. *Gastroenterology* 2002; **123**: 1084-1089
- 10 Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. *J Clin Microbiol* 2004; **42**: 4882-4884
- 11 Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. *Hepatology* 2007; **45**: 1187-1192
- 12 Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; **45**: 507-539
- 13 Bréchet C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchet P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? *Hepatology* 2001; **34**: 194-203
- 14 Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. *Immunol Rev* 2000; **174**: 98-111
- 15 Torbenson M, Thomas DL. Occult hepatitis B. *Lancet Infect Dis* 2002; **2**: 479-486
- 16 Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. *J Hepatol* 2007; **46**: 160-170
- 17 Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. *World J Gastroenterol* 2007; **13**: 5682-5686
- 18 Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, Gutkin A, Doucette K, Martin B, Giulivi A. Occult hepatitis B virus infection in a North American community-based population. *J Hepatol* 2005; **42**: 480-485
- 19 Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. *Hepatology* 2000; **31**: 488-495
- 20 Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. *Hepatology* 1998; **27**: 1736-1742
- 21 Allain JP. Occult hepatitis B virus infection: implications in transfusion. *Vox Sang* 2004; **86**: 83-91
- 22 Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. *J Clin Virol* 2006; **36** Suppl 1: S33-S44
- 23 Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. *J Hepatol* 2006; **44**: 39-46
- 24 Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. *Gastroenterology* 2004; **127**: 1356-1371
- 25 Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, Waters J, Karayiannis P, Luo K. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. *Hepatology* 2001; **34**: 1027-1034
- 26 Jeantet D, Chemin I, Mandrand B, Tran A, Zoulim F, Merle P, Trepo C, Kay A. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. *J Med Virol*

- 2004; **73**: 508-515
- 27 **Ahn SH**, Park YN, Park JY, Chang HY, Lee JM, Shin JE, Han KH, Park C, Moon YM, Chon CY. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. *J Hepatol* 2005; **42**: 188-194
- 28 **Chan HL**, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, Chan FK, Sung JJ. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. *Am J Gastroenterol* 2002; **97**: 1211-1215
- 29 **Minuk GY**, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. *Hepatology* 2004; **40**: 1072-1077
- 30 **Candotti D**, Allain JP. Transfusion-transmitted hepatitis B virus infection. *J Hepatol* 2009; **51**: 798-809
- 31 **Chemin I**, Trépo C. Clinical impact of occult HBV infections. *J Clin Virol* 2005; **34** Suppl 1: S15-S21
- 32 **Paterlini P**, Gerken G, Nakajima E, Terre S, D'Errico A, Grigioni W, Nalpas B, Franco D, Wands J, Kew M. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. *N Engl J Med* 1990; **323**: 80-85
- 33 **Tabor E**, Hoofnagle JH, Smallwood LA, Drucker JA, Pineda-Tamondong GC, Ni LY, Greenwalt TJ, Barker LF, Gerety RJ. Studies of donors who transmit posttransfusion hepatitis. *Transfusion* 1979; **19**: 725-731
- 34 **Ganem D**, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. *N Engl J Med* 2004; **350**: 1118-1129
- 35 **Bock CT**, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, Zentgraf H. Structural organization of the hepatitis B virus minichromosome. *J Mol Biol* 2001; **307**: 183-196
- 36 **Zoulim F**. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. *J Hepatol* 2005; **42**: 302-308
- 37 **Kreutz C**. Molecular, immunological and clinical properties of mutated hepatitis B viruses. *J Cell Mol Med* 2002; **6**: 113-143
- 38 **Chaudhuri V**, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. *Gastroenterology* 2004; **127**: 1356-1371
- 39 **Hass M**, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. *Hepatology* 2005; **42**: 93-103
- 40 **Pollicino T**, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. *Hepatology* 2007; **45**: 277-285
- 41 **Mulrooney-Cousins PM**, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. *World J Gastroenterol* 2007; **13**: 5682-5686
- 42 **Fourel G**, Couturier J, Wei Y, Apiou F, Tiollais P, Buendia MA. Evidence for long-range oncogene activation by hepadnavirus insertion. *EMBO J* 1994; **13**: 2526-2534
- 43 **Diao J**, Churchill ND, Michalak TI. Complement-mediated cytotoxicity and inhibition of ligand binding to hepatocytes by woodchuck hepatitis virus-induced autoantibodies to asialoglycoprotein receptor. *Hepatology* 1998; **27**: 1623-1631
- 44 **Michalak TI**. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. *Immunol Rev* 2000; **174**: 98-111
- 45 **Coffin CS**, Pham TN, Mulrooney PM, Churchill ND, Michalak TI. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. *Hepatology* 2004; **40**: 1053-1061
- 46 **Penna A**, Artini M, Cavalli A, Levrero M, Bertolotti A, Pilli M, Chisari FV, Rehermann B, Del Prete G, Fiaccadori F, Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. *J Clin Invest* 1996; **98**: 1185-1194
- 47 **Rehermann B**, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. *Nat Med* 1996; **2**: 1104-1108
- 48 **Lok AS**, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. *Gastroenterology* 1991; **100**: 182-188
- 49 **Marcellin P**, Giostra E, Martinot-Peignoux M, Lorient MA, Jaegle ML, Wolf P, Degott C, Degos F, Benhamou JP. Redevelopment of hepatitis B surface antigen after renal transplantation. *Gastroenterology* 1991; **100**: 1432-1434
- 50 **Jin YM**, Churchill ND, Michalak TI. Protease-activated lymphoid cell and hepatocyte recognition site in the preS1 domain of the large woodchuck hepatitis virus envelope protein. *J Gen Virol* 1996; **77** (Pt 8): 1837-1846
- 51 **Stoll-Becker S**, Repp R, Glebe D, Schaefer S, Kreuder J, Kann M, Lampert F, Gerlich WH. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. *J Virol* 1997; **71**: 5399-5407
- 52 **Laskus T**, Radkowski M, Wang LF, Nowicki M, Rakela J. Detection and sequence analysis of hepatitis B virus integration in peripheral blood mononuclear cells. *J Virol* 1999; **73**: 1235-1238
- 53 **Chemin I**, Vermot-Desroches C, Baginski I, Saurin JC, Laurent F, Zoulim F, Bernaud J, Lamelin JP, Hantz O, Rigal D. Selective detection of human hepatitis B virus surface and core antigens in peripheral blood mononuclear cell subsets by flow cytometry. *J Viral Hepat* 1994; **1**: 39-44
- 54 **Korba BE**, Cote PJ, Gerin JL. Mitogen-induced replication of woodchuck hepatitis virus in cultured peripheral blood lymphocytes. *Science* 1988; **241**: 1213-1216
- 55 **Coffin CS**, Michalak TI. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. *J Clin Invest* 1999; **104**: 203-212
- 56 **Hui CK**, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. *Gastroenterology* 2006; **131**: 59-68
- 57 **Madonia S**, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. *Inflamm Bowel Dis* 2007; **13**: 508-509
- 58 **Chamorro AJ**, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. *Eur J Clin Microbiol Infect Dis* 2005; **24**: 492-494
- 59 **Lalazar G**, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. *Br J Haematol* 2007; **136**: 699-712

S- Editor Tian L L- Editor Kerr C E- Editor Ma WH